- Home
- KZIA vs PRSO Comparison
KZIA vs PRSO Comparison
Compare KZIA & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- PRSO
- Stock Information
- Founded
- KZIA 1994
- PRSO 2008
- Country
- KZIA Australia
- PRSO United States
- Employees
- KZIA N/A
- PRSO N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- PRSO Semiconductors
- Sector
- KZIA Health Care
- PRSO Technology
- Exchange
- KZIA Nasdaq
- PRSO Nasdaq
- Market Cap
- KZIA 5.1M
- PRSO 6.1M
- IPO Year
- KZIA 1999
- PRSO 2001
- Fundamental
- Price
- KZIA $10.45
- PRSO $1.05
- Analyst Decision
- KZIA Strong Buy
- PRSO Strong Buy
- Analyst Count
- KZIA 2
- PRSO 1
- Target Price
- KZIA $14.00
- PRSO $3.00
- AVG Volume (30 Days)
- KZIA 745.7K
- PRSO 360.5K
- Earning Date
- KZIA 07-22-2025
- PRSO 08-11-2025
- Dividend Yield
- KZIA N/A
- PRSO N/A
- EPS Growth
- KZIA N/A
- PRSO N/A
- EPS
- KZIA N/A
- PRSO N/A
- Revenue
- KZIA $1,549,158.00
- PRSO $15,626,000.00
- Revenue This Year
- KZIA N/A
- PRSO $3.96
- Revenue Next Year
- KZIA N/A
- PRSO $36.80
- P/E Ratio
- KZIA N/A
- PRSO N/A
- Revenue Growth
- KZIA 248983.08
- PRSO 35.50
- 52 Week Low
- KZIA $2.86
- PRSO $0.52
- 52 Week High
- KZIA $79.00
- PRSO $2.34
- Technical
- Relative Strength Index (RSI)
- KZIA 72.75
- PRSO 46.99
- Support Level
- KZIA $5.86
- PRSO $1.00
- Resistance Level
- KZIA $7.20
- PRSO $1.23
- Average True Range (ATR)
- KZIA 1.17
- PRSO 0.09
- MACD
- KZIA 0.15
- PRSO -0.01
- Stochastic Oscillator
- KZIA 82.21
- PRSO 22.58
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About PRSO Peraso Inc.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.